Abstract
In 188 HIV-infected children receiving efavirenz, a lower mid-dose (C12) was associated with a higher risk of HIV-1 viral load >400 copies/mL (P = 0.03). Simulations for a normalized population receiving US Food and Drug Administration weight-band dosing predicted that 15% of children would have a C12 below target threshold (<1.0 mg/L) with a 23% risk of viral replication.
MeSH terms
-
Alkynes
-
Benzoxazines / blood*
-
Benzoxazines / pharmacokinetics
-
Benzoxazines / pharmacology
-
Benzoxazines / therapeutic use
-
Child
-
Cohort Studies
-
Cyclopropanes
-
Female
-
HIV Infections / drug therapy*
-
HIV Infections / virology*
-
HIV-1 / drug effects
-
Humans
-
Male
-
Reverse Transcriptase Inhibitors / blood*
-
Reverse Transcriptase Inhibitors / pharmacokinetics
-
Reverse Transcriptase Inhibitors / pharmacology
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Viral Load / drug effects*
Substances
-
Alkynes
-
Benzoxazines
-
Cyclopropanes
-
Reverse Transcriptase Inhibitors
-
efavirenz